Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
IronNet spikes 37% after announcing joining Microsoft Intelligent Security Assoc » 15:12
10/27/21
10/27
15:12
10/27/21
15:12
IRNT

IronNet

$13.81 /

+3.48 (+33.69%)

, MSFT

Microsoft

$325.37 /

+15.53 (+5.01%)

IronNet (IRNT) jumped 37%…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

IRNT IronNet
$13.81 /

+3.48 (+33.69%)

IRNT IronNet
$13.81 /

+3.48 (+33.69%)

09/29/21
Fly Intel: Top five analyst initiations
09/29/21 Jefferies
IronNet initiated with a Hold at Jefferies
09/27/21 Needham
IronNet initiated with a Buy at Needham
09/27/21 Needham
IronNet initiated with a Buy at Needham
MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

09:13 Today Wedbush
Microsoft delivers another 'World-Series' cloud performance, says Wedbush
08:41 Today Credit Suisse
Microsoft price target raised to $340 from $320 at Credit Suisse
08:33 Today Morgan Stanley
Microsoft price target raised to $364 from $331 at Morgan Stanley
08:24 Today Evercore ISI
Microsoft price target raised to $370 from $325 at Evercore ISI
MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

IRNT IronNet
$13.81 /

+3.48 (+33.69%)

MSFT Microsoft
$325.37 /

+15.53 (+5.01%)

IRNT IronNet
$13.81 /

+3.48 (+33.69%)

Options
IronNet Inc (Class A Stock) call volume above normal and directionally bullish » 10:45
10/27/21
10/27
10:45
10/27/21
10:45
IRNT

IronNet

$10.67 /

+0.34 (+3.29%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
IRNT IronNet
$10.67 /

+0.34 (+3.29%)

IRNT IronNet
$10.67 /

+0.34 (+3.29%)

09/29/21
Fly Intel: Top five analyst initiations
09/29/21 Jefferies
IronNet initiated with a Hold at Jefferies
09/27/21 Needham
IronNet initiated with a Buy at Needham
09/27/21 Needham
IronNet initiated with a Buy at Needham
IRNT IronNet
$10.67 /

+0.34 (+3.29%)

IRNT IronNet
$10.67 /

+0.34 (+3.29%)

Yesterday
Earnings
Usana backs FY21 EPS view of $5.80-$6.00, two estimates $5.93 » 16:20
10/26/21
10/26
16:20
10/26/21
16:20
USNA

Usana

$99.95 /

-0.58 (-0.58%)

Backs FY21 revenue view…

Backs FY21 revenue view of $1.18B-$1.20B, two estimates $1.19B

ShowHide Related Items >><<
USNA Usana
$99.95 /

-0.58 (-0.58%)

USNA Usana
$99.95 /

-0.58 (-0.58%)

10/08/21 Tigress Financial
Usana shares have 27% upside in 12 months, says Tigress Financial
02/10/21 Roth Capital
Usana price target raised to $126 from $107 at Roth Capital
12/17/20 Roth Capital
Usana initiated with a Buy at Roth Capital
USNA Usana
$99.95 /

-0.58 (-0.58%)

USNA Usana
$99.95 /

-0.58 (-0.58%)

Earnings
Usana reports Q3 EPS $1.36, two estimates $1.30 » 16:19
10/26/21
10/26
16:19
10/26/21
16:19
USNA

Usana

$99.95 /

-0.58 (-0.58%)

Reports Q3 revenue…

Reports Q3 revenue $274.4M, two estimates $268.06M. "As we indicated a month ago, the operating environment remains challenging across several of our key markets due, in great part, to disruptions and lockdowns related to the COVID-19 pandemic," said Kevin Guest, CEO. "Additionally, the year-over-year comparison was difficult given the significant short-term sales program that we offered in the prior year quarter. Notwithstanding these challenges, we continue to execute our growth strategy, which is centered on generating sustainable customer growth. We made progress on several strategic initiatives during the quarter. Enhancing the overall shopping experience for our customers remains a high priority, and to that end, we rolled out additional features and functionality within our China shopping app, as well as a new web-based shopping cart in China. Although our introduction of certain new products has been delayed until 2022, we are actively engaged in bringing new and innovative products to market. Overall, we remain confident that the successful execution of our strategy will deliver long-term, sustainable growth."

ShowHide Related Items >><<
USNA Usana
$99.95 /

-0.58 (-0.58%)

USNA Usana
$99.95 /

-0.58 (-0.58%)

10/08/21 Tigress Financial
Usana shares have 27% upside in 12 months, says Tigress Financial
02/10/21 Roth Capital
Usana price target raised to $126 from $107 at Roth Capital
12/17/20 Roth Capital
Usana initiated with a Buy at Roth Capital
USNA Usana
$99.95 /

-0.58 (-0.58%)

USNA Usana
$99.95 /

-0.58 (-0.58%)

Recommendations
Diamondback Energy price target raised to $147 from $127 at Mizuho » 06:45
10/26/21
10/26
06:45
10/26/21
06:45
FANG

Diamondback Energy

$109.44 /

+0.18 (+0.16%)

Mizuho analyst Vincent…

Mizuho analyst Vincent Lovaglio raised the firm's price target on Diamondback Energy to $147 from $127 and keeps a Buy rating on the shares. The analyst increased price targets across the oil exploration and production group ahead of Q3 earnings citing increasing confidence in a second half of 2022 call on U.S. unconventional oil growth. Energy is poised to outperform and exploration and production is positioned to lead, Lovaglio tells investors in a research note.

ShowHide Related Items >><<
FANG Diamondback Energy
$109.44 /

+0.18 (+0.16%)

FANG Diamondback Energy
$109.44 /

+0.18 (+0.16%)

10/21/21 Piper Sandler
Diamondback Energy price target raised to $131 from $112 at Piper Sandler
10/19/21 Roth Capital
Diamondback Energy price target raised to $135 from $115 at Roth Capital
10/07/21 Truist
Diamondback Energy price target raised to $148 from $130 at Truist
09/28/21 Citi
Citi names Pioneer Natural top E&P pick, ups target to $215
FANG Diamondback Energy
$109.44 /

+0.18 (+0.16%)

FANG Diamondback Energy
$109.44 /

+0.18 (+0.16%)

FANG Diamondback Energy
$109.44 /

+0.18 (+0.16%)

Monday
Recommendations
Agenus price target lowered to $11 from $12 at B. Riley » 08:11
10/25/21
10/25
08:11
10/25/21
08:11
AGEN

Agenus

$4.01 /

-1.12 (-21.85%)

B. Riley analyst Mayank…

B. Riley analyst Mayank Mamtani lowered the firm's price target on Agenus to $11 from $12 and reiterates a Buy rating on the shares. The company unexpectedly announced the decision to voluntarily withdraw the application for its anti PD-1 drug candidate, balstilimab, ahead of the original December 16 action date date at the FDA's recommendation following agency granting full approval to Merck's Keytruda four months earlier than its target action date, Mamtani tells investors in a research note. The analyst views the update as disappointing.

ShowHide Related Items >><<
AGEN Agenus
$4.01 /

-1.12 (-21.85%)

AGEN Agenus
$4.01 /

-1.12 (-21.85%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
AGEN Agenus
$4.01 /

-1.12 (-21.85%)

AGEN Agenus
$4.01 /

-1.12 (-21.85%)

AGEN Agenus
$4.01 /

-1.12 (-21.85%)

Friday
Options
Largest borrow rate increases among liquid names » 08:45
10/22/21
10/22
08:45
10/22/21
08:45
DNA

Ginkgo Bioworks

$13.20 /

-0.55 (-4.00%)

, HOOD

Robinhood

$41.25 /

-0.57 (-1.36%)

, SKIN

Beauty Health

$27.22 /

+0.24 (+0.89%)

, RKLB

Rocket Lab

$12.66 /

-0.07 (-0.55%)

, CIFR

Cipher Mining

$8.33 /

-0.41 (-4.69%)

, OPAD

Offerpad Solutions

$7.77 /

-0.415 (-5.07%)

, MVST

Microvast

$8.10 /

-0.005 (-0.06%)

, SPIR

Spire Global

$5.68 /

-0.05 (-0.87%)

, LICY

Li-Cycle

$11.40 /

-0.255 (-2.19%)

, DOLE

Dole

$15.44 /

+0.09 (+0.59%)

Latest data shows the…

Latest data shows the largest indicative borrow rate increases among liquid option names include: (DNA) 162.59% +53.05, Robinhood Markets (HOOD) 179.03% +12.42, Beauth Health Company (SKIN) 11.00% +10.67, Rocket Lab USA (RKLB) 46.22% +9.10, (CIFR) 145.69% +4.39, (OPAD) 69.10% +2.42, Microvast Holdings (MVST) 120.00% +2.02, Spire Global (SPIR) 65.92% +1.39, Li Cycle Holdings Corp (LICY) 29.86% +1.02, and (DOLE) 1.38% +0.50.

ShowHide Related Items >><<
SPIR Spire Global
$5.68 /

-0.05 (-0.87%)

SKIN Beauty Health
$27.22 /

+0.24 (+0.89%)

RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

OPAD Offerpad Solutions
$7.77 /

-0.415 (-5.07%)

MVST Microvast
$8.10 /

-0.005 (-0.06%)

LICY Li-Cycle
$11.40 /

-0.255 (-2.19%)

HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

DOLE Dole
$15.44 /

+0.09 (+0.59%)

DNA Ginkgo Bioworks
$13.20 /

-0.55 (-4.00%)

CIFR Cipher Mining
$8.33 /

-0.41 (-4.69%)

DNA Ginkgo Bioworks
$13.20 /

-0.55 (-4.00%)

10/20/21 Raymond James
Raymond James expects more equity-based payments for Ginkgo as milestones met
10/13/21 Raymond James
Ginkgo Bioworks initiated with an Outperform at Raymond James
10/12/21 William Blair
Blair starts Ginkgo at Outperform on 'significant' competitive advantage
10/12/21 William Blair
Ginkgo Bioworks initiated with an Outperform at William Blair
HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

10/22/21 JPMorgan
Robinhood shares 'vulnerable' with liquidity coming, says JPMorgan
10/05/21 Mizuho
Most Robinhood users would pay small fee to stay on platform, says Mizuho
08/23/21
Fly Intel: Top five analyst initiations
08/23/21 Rosenblatt
Robinhood initiated with a Buy at Rosenblatt
SKIN Beauty Health
$27.22 /

+0.24 (+0.89%)

10/07/21 Stifel
Beauty Health initiated with a Buy at Stifel
10/04/21 Cowen
Cowen sees Beauty Health as category leader, starts with Outperform
10/04/21 Cowen
Beauty Health initiated with an Outperform at Cowen
09/20/21 Piper Sandler
Beauty Health could have 'robust year' in 2022, says Piper Sandler
RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

10/04/21 BofA
Astra initiated with an Underperform at BofA
09/30/21 Stifel
Rocket Lab initiated with a Buy at Stifel
09/17/21 Deutsche Bank
Rocket Lab initiated with a Buy at Deutsche Bank
09/13/21 Cowen
Rocket Lab USA initiated with a Market Perform at Cowen
CIFR Cipher Mining
$8.33 /

-0.41 (-4.69%)

OPAD Offerpad Solutions
$7.77 /

-0.415 (-5.07%)

10/14/21 JMP Securities
Offerpad Solutions initiated with an Outperform at JMP Securities
09/27/21 Jefferies
Offerpad Solutions initiated with a Hold at Jefferies
MVST Microvast
$8.10 /

-0.005 (-0.06%)

08/03/21 Morgan Stanley
Microvast initiated with an Underweight at Morgan Stanley
SPIR Spire Global
$5.68 /

-0.05 (-0.87%)

10/14/21 Piper Sandler
Spire Global initiated with a Neutral at Piper Sandler
09/08/21 Baird
Baird starts Spire at Neutral, taking 'wait and see approach'
09/08/21 Baird
Spire Corporation initiated with a Neutral at Baird
LICY Li-Cycle
$11.40 /

-0.255 (-2.19%)

10/18/21 Citi
Li-Cycle initiated with a Buy at Citi
09/22/21 UBS
Li-Cycle initiated with a Buy at UBS
09/20/21 Wedbush
Li-Cycle initiated with an Outperform at Wedbush
09/13/21 Morgan Stanley
Li-Cycle initiated with an Overweight at Morgan Stanley
DOLE Dole
$15.44 /

+0.09 (+0.59%)

08/24/21
Fly Intel: Top five analyst initiations
08/24/21 BofA
BofA starts Dole at Underperform, says stock 'not ripe enough'
08/24/21 Stephens
Dole initiated with an Overweight at Stephens
08/24/21 Stephens
Dole initiated with an Overweight at Stephens
SKIN Beauty Health
$27.22 /

+0.24 (+0.89%)

RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

MVST Microvast
$8.10 /

-0.005 (-0.06%)

LICY Li-Cycle
$11.40 /

-0.255 (-2.19%)

HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

  • 30
    Jul
  • 29
    Jul
RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

DOLE Dole
$15.44 /

+0.09 (+0.59%)

DNA Ginkgo Bioworks
$13.20 /

-0.55 (-4.00%)

SKIN Beauty Health
$27.22 /

+0.24 (+0.89%)

RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

OPAD Offerpad Solutions
$7.77 /

-0.415 (-5.07%)

MVST Microvast
$8.10 /

-0.005 (-0.06%)

LICY Li-Cycle
$11.40 /

-0.255 (-2.19%)

HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

DOLE Dole
$15.44 /

+0.09 (+0.59%)

DNA Ginkgo Bioworks
$13.20 /

-0.55 (-4.00%)

SPIR Spire Global
$5.68 /

-0.05 (-0.87%)

SKIN Beauty Health
$27.22 /

+0.24 (+0.89%)

RKLB Rocket Lab
$12.66 /

-0.07 (-0.55%)

OPAD Offerpad Solutions
$7.77 /

-0.415 (-5.07%)

MVST Microvast
$8.10 /

-0.005 (-0.06%)

LICY Li-Cycle
$11.40 /

-0.255 (-2.19%)

HOOD Robinhood
$41.25 /

-0.57 (-1.36%)

DOLE Dole
$15.44 /

+0.09 (+0.59%)

DNA Ginkgo Bioworks
$13.20 /

-0.55 (-4.00%)

CIFR Cipher Mining
$8.33 /

-0.41 (-4.69%)

Hot Stocks
Agenus withdraws BLA for balstilimab, decides to discontinue BRAVA trial » 08:05
10/22/21
10/22
08:05
10/22/21
08:05
AGEN

Agenus

$5.13 /

+0.115 (+2.30%)

Agenus announced a…

Agenus announced a strategic decision to withdraw its Biologics License Application for balstilimab, its PD-1 inhibitor. The decision to withdraw the BLA does not change the development plans for balstilimab combinations. Following the full approval of pembrolizumab, announced four months earlier than the FDA goal date, the U.S. Food and Drug Administration no longer considered it appropriate to review the BLA for accelerated approval and recommended Agenus withdraw. The BLA submission for balstilimab received Fast Track and Priority Review designation from the FDA, with a target action date of December 16, 2021. As part of the BLA review process, Agenus completed 3 FDA inspections with no cited issues, concerns, or Form-483s. As previously reported, in the largest single-arm trial to date in this population, balstilimab demonstrated objective responses in both PD-L1 positive and negative patients, with an objective response rate of 20% and 8% respectively. Pembrolizumab has demonstrated an ORR of 14% and 0% in PD-L1 positive and negative patients respectively, which led to its accelerated approval in 2018. Balstilimab has shown superior killing of PD-L1 negative tumors compared to other anti PD-1 therapies, including pembrolizumab, suggesting a broader mechanism consistent with balstilimab's clinical activity in both PD-L1 positive and negative cervical cancer2. Concurrent with the withdrawal, Agenus will discontinue its ongoing confirmatory trial in this population, which is expected to reduce R&D expenses by over $100M. However, given the clinical benefit demonstrated by balstilimab, Agenus plans to launch expanded access programs to give patients and doctors access to balstilimab in several countries, including the US, pending regulatory processes.

ShowHide Related Items >><<
AGEN Agenus
$5.13 /

+0.115 (+2.30%)

AGEN Agenus
$5.13 /

+0.115 (+2.30%)

09/07/21 B. Riley
Agenus price target raised to $12 from $11 at B. Riley
06/28/21 B. Riley
Agenus price target raised to $11 from $8 at B. Riley
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
AGEN Agenus
$5.13 /

+0.115 (+2.30%)

AGEN Agenus
$5.13 /

+0.115 (+2.30%)

AGEN Agenus
$5.13 /

+0.115 (+2.30%)

Thursday
Hot Stocks
Rattler Midstream to acquire certain assets from Diamondback Energy for $160M » 16:11
10/21/21
10/21
16:11
10/21/21
16:11
RTLR

Rattler Midstream

$12.48 /

-0.63 (-4.81%)

, FANG

Diamondback Energy

$108.84 /

-2.27 (-2.04%)

Rattler Midstream (RTLR)…

Rattler Midstream (RTLR) announced that Rattler Midstream Operating entered into a definitive purchase agreement to acquire certain water midstream assets from subsidiaries of Diamondback Energy (FANG) for $160M in cash in a drop down transaction. The assets subject to the drop down consist primarily of produced water gathering and disposal systems, produced water recycling facilities, and sourced water gathering and storage assets acquired by Diamondback through transactions with QEP Resources, Inc. and Guidon Operating and certain of its affiliates in early 2021. Additionally, Rattler and Diamondback have mutually agreed to amend commercial agreements covering the produced water gathering and disposal and sourced water gathering services between Rattler and Diamondback to add certain Diamondback leasehold acreage to the Rattler dedication. Rattler intends to fund the transaction, expected to close in Q4, through cash on hand and borrowings under its revolving credit facility.

ShowHide Related Items >><<
RTLR Rattler Midstream
$12.48 /

-0.63 (-4.81%)

FANG Diamondback Energy
$108.84 /

-2.27 (-2.04%)

RTLR Rattler Midstream
$12.48 /

-0.63 (-4.81%)

08/13/21 Barclays
Barclays cuts Rattler Midstream to Underweight, sees limited near-term growth
08/13/21 Barclays
Rattler Midstream downgraded to Underweight from Equal Weight at Barclays
08/02/21 JPMorgan
Rattler Midstream assumed with an Overweight at JPMorgan
04/15/21 Raymond James
Rattler Midstream upgraded to Outperform from Market Perform at Raymond James
FANG Diamondback Energy
$108.84 /

-2.27 (-2.04%)

10/21/21 Piper Sandler
Diamondback Energy price target raised to $131 from $112 at Piper Sandler
10/19/21 Roth Capital
Diamondback Energy price target raised to $135 from $115 at Roth Capital
10/07/21 Truist
Diamondback Energy price target raised to $148 from $130 at Truist
09/28/21 Citi
Citi names Pioneer Natural top E&P pick, ups target to $215
RTLR Rattler Midstream
$12.48 /

-0.63 (-4.81%)

FANG Diamondback Energy
$108.84 /

-2.27 (-2.04%)

FANG Diamondback Energy
$108.84 /

-2.27 (-2.04%)

FANG Diamondback Energy
$108.84 /

-2.27 (-2.04%)

Recommendations
Diamondback Energy price target raised to $131 from $112 at Piper Sandler » 06:05
10/21/21
10/21
06:05
10/21/21
06:05
FANG

Diamondback Energy

$111.19 /

+0.35 (+0.32%)

Piper Sandler analyst…

Piper Sandler analyst Mark Lear raised the firm's price target on Diamondback Energy to $131 from $112 and keeps an Overweight rating on the shares into the Q3 reporting season. While 2021 was largely anticipated to be a balance sheet repair year for domestic exploration and production companies, stronger than expected commodity prices have pulled forward shareholder return plans, Lear tells investors in a research note. The group is broadly anticipated to reduce capex and execute maintenance budgets in 2022, "which ultimately should bring investors back to the sector," says the analyst.

ShowHide Related Items >><<
FANG Diamondback Energy
$111.19 /

+0.35 (+0.32%)

FANG Diamondback Energy
$111.19 /

+0.35 (+0.32%)

10/19/21 Roth Capital
Diamondback Energy price target raised to $135 from $115 at Roth Capital
10/07/21 Truist
Diamondback Energy price target raised to $148 from $130 at Truist
09/28/21 Citi
Citi names Pioneer Natural top E&P pick, ups target to $215
09/15/21 Truist
Diamondback Energy price target raised to $130 from $122 at Truist
FANG Diamondback Energy
$111.19 /

+0.35 (+0.32%)

FANG Diamondback Energy
$111.19 /

+0.35 (+0.32%)

FANG Diamondback Energy
$111.19 /

+0.35 (+0.32%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.